DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Simtuzumab is an investigational drug.
There have been 6 clinical trials for Simtuzumab. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2011.
The most common disease conditions in clinical trials are Fibrosis, Adenocarcinoma, and Pulmonary Fibrosis. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].
There are twelve US patents protecting this investigational drug and two hundred and twenty-two international patents.
Recent Clinical Trials for Simtuzumab
|Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3||Gilead Sciences||Phase 2|
|A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)||Gilead Sciences||Phase 2|
|Long-Term Safety Study of GS-6624 to Treat Idiopathic Pulmonary Fibrosis (IPF)||Gilead Sciences||Phase 2|
Top disease conditions for Simtuzumab
Top clinical trial sponsors for Simtuzumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Simtuzumab||Start Trial||Compositions comprising oxo-derivatives of fatty acids and methods of making and using same||DS BIOPHARMA LIMITED (Dublin, IE)||Start Trial|
|Simtuzumab||Start Trial||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||Start Trial|
|Simtuzumab||Start Trial||Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same||Afimmune Limited (IE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Simtuzumab||European Patent Office||3294282||2035-05-13||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|